Follicular thyroid cancer surgery

	Follicular thyroid cancer Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Follicular thyroid cancer from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
X-ray
Echocardiography and Ultrasound
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Follicular thyroid cancer surgery On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Follicular thyroid cancer surgery All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Follicular thyroid cancer surgery
CDC on Follicular thyroid cancer surgery
Follicular thyroid cancer surgery in the news
Blogs on Follicular thyroid cancer surgery
Directions to Hospitals Treating Follicular thyroid cancer
Risk calculators and risk factors for Follicular thyroid cancer surgery

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]

Overview

Surgery is the mainstay of treatment for follicular thyroid cancer.

Unilateral hemithyroidectomy is uncommon due to the aggressive nature of follicular thyroid cancer.^[1]
Total thyroidectomy is the mainstay of treatment for follicular thyroid cancer. This is invariably followed by radioiodine treatment at levels from 50 to 200 millicuries following two weeks of a low iodine diet (LID). Occasionally treatment must be repeated if annual scans indicate remaining cancerous tissue.

The objective of surgery is to completely remove the primary tumor, while minimizing treatment-related morbidity, and to guide postoperative treatment with radioactive iodine (RAI). The goal of radioactive iodine (RAI) is to ablate the remnant thyroid tissue to improve the specificity of thyroglobulin assays, which allows the detection of persistent disease by follow-up whole-body scanning. For patients undergoing radioactive iodine (RAI), removal of all normal thyroid tissue is an important surgical objective. Additionally, for accurate long-term surveillance, radioactive iodine (RAI) whole-body scanning and measurement of serum thyroglobulin are affected by residual, normal thyroid tissue, and in these situations, near total or total thyroidectomy is required. This approach facilitates follow-up thyroid scanning.

Lobectomy is associated with a lower incidence of complications, but approximately 5% to 10% of patients will have a recurrence in the thyroid following lobectomy. Patients younger than 45 years will have the longest follow-up period and the greatest opportunity for recurrence. Follicular thyroid cancer commonly metastasizes to lungs and bone; with a remnant lobe in place, use of I-131 as ablative therapy is compromised. Abnormal regional lymph nodes should be biopsied at the time of surgery. Recognized nodal involvement should be removed at initial surgery, but selective node removal can be performed, and radical neck dissection is usually not required. This results in a decreased recurrence rate but has not been shown to improve survival.
Following the surgical procedure, patients should receive postoperative treatment with exogenous thyroid hormone in doses sufficient to suppress thyroid-stimulating hormone (TSH); studies have shown a decreased incidence of recurrence when thyroid-stimulating hormone is suppressed.

Total thyroidectomy and removal of involved lymph nodes or other sites of extrathyroid disease.
I-131 ablation following total thyroidectomy if the tumor demonstrates uptake of this isotope.
External-beam radiation therapy if I-131 uptake is minimal

The most common sites of metastases are lymph nodes, lung, and bone. Treatment of lymph node metastases alone is often curative. Treatment of distant metastases is usually not curative but may produce significant palliation.

For lymph node metastasis, central neck dissection is recommended.
Central neck dissection includes evacuation of fibrofatty and nodal tissue from common carotid artery to hyoid bones superiorly and inferiorly upto the innominate artery.
Modified neck dissection is reserved for lymph nodes with macroscopic metastasis. In this procedure, all nodal and fibrofatty tissues are removed from levels II to level V in the neck.